white → yellow2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
25B-NBOH
2C-B-NBOH
NBOH-2C-B
25B-NBOH is a synthetic psychedelic of the substituted phenethylamine class, derived from 2C-B through N-benzylation.citation needed First synthesized in 2011 by Martin Hansen at the University of Copenhagen, it is a close structural analog of 25B-NBOMe and is reported to share most of its properties, with moderately reduced potency and a shorter duration. It produces visually dominant and stimulating psychedelic effects, acting as a potent serotonin receptor agonist at 5-HT2A and 5-HT2C receptors.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~100 μg
Light100-400 μg
Moderate400-800 μg
Strong800-1000 μg
Heavy1000+ μg
Administration typically produces a strong metallic taste and significant numbness of the mouth and tongue, which may persist for up to an hour.
Duration
Onset20-40 minutes
After Effects1-12 hours
Total4-10 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
25B-NBOH produces a stimulating psychedelic experience broadly comparable to other N-benzyl phenethylamines, combining euphoria, enhanced empathy, and a sense of insight with both open- and closed-eye visuals. The state is accompanied by pronounced mental and physical stimulation, and perception is noticeably altered throughout. Alongside its recreational qualities, the experience carries a distinct body load that includes restlessness, muscle tension, and alternating sweating and chills.
Physical
The body load is stimulating and somewhat uncomfortable, with restlessness, muscle tension, sweating and chills, suppressed appetite, and difficulty sleeping while the effects persist.
Stimulation
Uncomfortable
Cognitive
The headspace is euphoric and empathogenic, with a sense of insight and a softening of ego boundaries; confusion can also occur, particularly as effects intensify.
Emotional
Visual
Visual effects occur with eyes both open and closed and include a general brightening of color.
Tactile
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
25B-NBOH has been characterized as an agonist in assays at 5-HT2A and 5-HT2C receptors. The reported binding values are pKi 9.4 at human 5-HT2A and pKi 8.3 at rat 5-HT2C, with a reported 5-HT2A functional potency of pEC50 9.87. Because those measurements cover only two receptor subtypes and the binding measurements use receptors from different species, they do not establish broad receptor selectivity. In rats trained to discriminate the psychedelic DOM, 25B-NBOH fully substituted for the DOM cue, supporting hallucinogen-like discriminative-stimulus activity in that animal model.
Pharmacokinetics
A 2024 pooled-human-liver-microsome study identified in-vitro phase I and phase II metabolism of 25B-NBOH, including O-demethylation, hydroxylation, dehydrogenation, N-dehydroxybenzyl and N-demethoxybenzyl transformations, oxidation to ketone and carboxylate products, glucuronidation, and combined reactions. The authors proposed three high-abundance products as forensic biomarkers. Because the experiment used liver microsomes, it does not establish human oral bioavailability, plasma exposure, clearance, or elimination half-life.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Develops almost immediately after ingestion.
Baseline Reset
Approximately 2 weeks
Half Tolerance
Approximately 1 week
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely Low25B-NBOH is generally not described as habit-forming, and repeated use may reduce interest in taking it. Use is commonly characterized as self-regulating.
Toxicity
Cardiovascular
Acute cardiovascular effects including increased heart rate, elevated blood pressure, abnormal heartbeat, and vasoconstriction occur during intoxication;citation needed the long-term clinical significance in occasional users is not characterized due to limited research.
Psychosis Risk
Anxiety and paranoia appear to occur more readily than with many other psychedelics, potentially due to the compound's prominent stimulating properties. High doses can lead to states of confusion, amnesia, and general sensory overload. Unpredictable dose-response effects may contribute to psychological risk.
Seizure Risk
Seizures are listed among reported physical effects, though frequency and precipitating conditions are not well characterized due to limited human data.
History & Culture
25B-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a structural derivative of the phenethylamine psychedelic 2C-B, belonging to the broader family of N-benzyl phenethylamines and sharing close structural relationships with the…
Legality
By Country
Illegal2
United KingdomClass AClassified as a Class A controlled substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all provision.7 Class A substances carry the most severe penalties under UK drug law.
Controlled / restricted3
BrazilControlled (Portaria SVS/MS nº 344)Added to the controlled substances list under Portaria SVS/MS nº 344 on December 10, 2018.1 Possession, distribution, and use are prohibited under Brazilian law.
GermanyControlled (NpSG)Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.2 Production and import with intent to distribute, administration to others, and commercial trading are criminally punishable.3 Personal possession is prohibited but not subject to criminal penalty.4
Not scheduled1
United StatesUnscheduledNot explicitly scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption may be prosecuted under the Federal Analogue Act8 due to structural and pharmacological similarities to the Schedule I substance 25B-NBOMe.
References
Source Pages
Citations
- Resolução da Diretoria Colegiada – RDC Nº 254, de 10 de dezembro de 2018. (n.d.). https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2018/rdc0254_10_12_2018.pdf1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG). (n.d.). https://www.gesetze-im-internet.de/npsg/1
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html1
- Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act. (n.d.). https://pmc.ncbi.nlm.nih.gov/articles/PMC9632031/1
- Föreskrifter (HSLF-FS 2015:35) om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. (n.d.). https://lagen.nu/hslf-fs/2015:3512
- Verordnung des EDI über die Verzeichnisse der Betäubungsmittel (BetmVV-EDI), SR 812.121.11 – Anhang 6 (Verzeichnis e), Nummer 131. (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20250515/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20250515-de-pdf-a.pdf12
- http://www.legislation.gov.uk/uksi/2014/1106/made. (2014). http://www.legislation.gov.uk/uksi/2014/1106/made1
- 21 U.S.C. § 813 – Treatment of Controlled Substance Analogues. (n.d.). https://www.law.cornell.edu/uscode/text/21/8131
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25B-NBOH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.